Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 458, 290-292 (19 March 2009) | doi:10.1038/458290a; Published online 18 March 2009
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
- More Challenges
- Powered by:
nature jobs
Laboratory Technician (Pharmaceutical Analysis & Quality Control)
- Alliance Institute of Advanced Pharmacy and Health Sciences
- Hyderabad 500038 India
Dermapathologist
- Indiana University School of Medicine
- Indiana, USA
Cancer: The nuances of therapy
Lee M. Ellis1 & David A. Reardon2
Abstract
Oncologists use drugs that limit a tumour's blood supply to prevent its growth. Although the initial effects of these drugs are beneficial to patients, new data suggest that their long-term effects warrant further study.
Angiogenesis — the formation of new blood vessels — is a hallmark of cancer, and allows tumour growth. Anti-angiogenic therapy offers great promise and is often used to treat cancer, either alone or in combination with chemotherapy.
- Lee M. Ellis is in the Departments of Cancer Biology and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Email: lellis@mdanderson.org - David A. Reardon is at the Preston Robert Tisch Brain Tumour Center, Duke University Medical Center, Durham, North Carolina 27710, USA.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Reply to: ?Will integrin inhibitors have proangiogenic effects in the clinic??Nature Medicine Correspondence (01 Jul 2009)
